Is bupropion (Wellbutrin) appropriate for a patient with hypertension and a history of arteriovenous malformation (AVM)?

Bupropion (Wellbutrin) Should Be Avoided in Patients with Hypertension and History of AVM

Bupropion is contraindicated or should be avoided in this patient due to the combination of hypertension and history of arteriovenous malformation (AVM), as the medication can elevate blood pressure and increase seizure risk—both of which pose serious threats to AVM stability and hemorrhage risk.

Primary Concerns

Hypertension Risk with Bupropion

The FDA drug label explicitly warns that bupropion can result in elevated blood pressure and hypertension 1. The label mandates:

• Blood pressure assessment before initiating treatment
• Periodic monitoring during treatment
• Recognition that hypertension risk increases with concomitant use of drugs that increase dopaminergic or noradrenergic activity

Clinical trial data demonstrate:

• Statistically significant mean systolic BP increase of 1.3 mmHg (p=0.013) in seasonal affective disorder trials 1
• In patients with pre-existing stable congestive heart failure, bupropion caused exacerbation of baseline hypertension in 2 subjects, leading to treatment discontinuation 1
• 2% of patients (11/537) developed hypertension as an adverse reaction versus 0% in placebo groups 1

Critical AVM Considerations

Patients with AVM history face 2-4% annual hemorrhage risk, with mortality from first hemorrhage between 10-30% 2. The primary goal of AVM management is to eliminate intracerebral hemorrhage risk and preserve neurological function 3.

Hypertension is a major modifiable risk factor for AVM hemorrhage. Any medication that elevates blood pressure directly threatens AVM stability and increases catastrophic bleeding risk.

Seizure Risk Compounding the Problem

Bupropion carries a dose-dependent seizure risk of 0.4% at 300-450 mg/day 1. The FDA label specifically states that bupropion is contraindicated in patients with conditions that predispose to seizure, including stroke and brain metastases 4, 1.

While AVM is not explicitly listed, seizures can:

• Acutely elevate blood pressure
• Increase risk of AVM rupture
• Complicate neurological monitoring in patients with cerebrovascular disease

Evidence-Based Guideline Recommendations

Hypertension Management Guidelines

The 2016 AACE/ACE obesity guidelines explicitly state: "Naltrexone ER/bupropion ER should be avoided if other weight-loss medications can be used because weight loss assisted by naltrexone ER/bupropion ER cannot be expected to reduce blood pressure, and the drug is contraindicated in uncontrolled hypertension" 5.

The 2024 ESC hypertension guidelines recommend ACE inhibitors, ARBs, dihydropyridine CCBs, and thiazide diuretics as first-line treatments for blood pressure control 6. Bupropion does not appear in any hypertension treatment algorithm.

Smoking Cessation Context

If bupropion is being considered for smoking cessation, the 2016 NCCN guidelines note that bupropion is contraindicated for patients with seizure risks (including stroke, brain metastases) 4. While the guidelines don't specifically mention AVM, the cerebrovascular pathology is analogous.

Research in cardiovascular disease patients shows bupropion can be used cautiously 7, but these studies excluded patients with uncontrolled hypertension and cerebrovascular disease.

Alternative Recommendations

For Depression/ADHD Treatment

• First-line alternatives: SSRIs, SNRIs (excluding those that significantly elevate BP like venlafaxine at high doses)
• Atomoxetine for ADHD (though monitor BP) 8
• Avoid stimulants due to hypertension

For Smoking Cessation

• Varenicline is preferred if no contraindications 4
• Nicotine replacement therapy (NRT) - combination therapy acceptable 4
• Note: Varenicline is contraindicated in patients with brain metastases due to seizure risk 4, but AVM is not explicitly listed

For Weight Loss (if applicable)

• Liraglutide 3.0 mg, lorcaserin, or orlistat are preferred in patients with hypertension 5, 9
• Avoid naltrexone/bupropion combination 5

Clinical Monitoring If Bupropion Must Be Used

If no alternatives exist and the clinical indication is compelling:

1. Ensure hypertension is optimally controlled (target <130/80 mmHg per current guidelines 6, 10)
2. Neurology/neurosurgery consultation regarding AVM stability
3. Start at lowest dose (100-150 mg daily) with very gradual titration 8
4. Weekly BP monitoring for first month, then biweekly
5. Immediate discontinuation if BP rises >10 mmHg systolic or any neurological symptoms develop
6. Avoid doses >300 mg/day to minimize seizure risk 1

Common Pitfalls to Avoid

• Do not assume "history of AVM" means treated/obliterated AVM - verify complete obliteration on angiography before considering any BP-elevating medication
• Do not rely solely on office BP measurements - use home BP monitoring or ambulatory BP monitoring 6
• Do not combine with other sympathomimetic agents (including decongestants, stimulants) 1
• Do not dismiss small BP elevations - even modest increases can be catastrophic in AVM patients

The risk-benefit analysis strongly favors avoiding bupropion in this population and selecting alternative therapies that do not elevate blood pressure or seizure risk.